Phaseline

Targets › FCRN

FCRN (IgG receptor FcRn large subunit p51): drug programs, companies and trials

1 program from 1 company in 8 trials: 3 Phase 3, 3 Phase 2, 2 Phase 1; Neurology, Immunology, Other; next expected readout Nov 2026.

Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. (UniProt, P55899)

Open in Phaseline: the race on FCRN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
argenxEmpasiprubart
FcRn antagonist
FCRN, FCRL5Phase 3Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis …Nov 2026

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (2) Multifocal Motor Neuropathy (MMN) (2) AChR-Ab Seropositive Generalized Myasthenia Gravis (2) Dermatomyositis (1) Healthy Volunteers (1)

Modalities

antibody (1)

Companies

argenx (1)

Related targets

FCRL5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.